✦ LIBER ✦

Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease

✍ Scribed by Xu Yue; Torsten Falk; Leslie A. Zuniga; Lajos Szabò; Frank Porreca; Robin Polt; Scott J. Sherman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiparkinsonian Action of a δ Opioid Ag

✍ C.J. Hille; S.H. Fox; Y.P. Maneuf; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 177 KB

The role of opioid receptor agonists and

✍ I. G. Silkis 📂 Article 📅 2007 🏛 SP MAIK Nauka/Interperiodica 🌐 English ⚖ 473 KB

A.2 The preclinical profile of rotigotin

✍ P. Jenner 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Evaluation of the mGluR2/3 agonist LY379

✍ Tracey K Murray; Marcus J Messenger; Mark A Ward; Sandra Woodhouse; David J Osbo 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 491 KB

Partial lessons of the nigrostriatal pat

✍ J. Fornaguera-Trias; R.K.W. Schwarting; F. Boix; J.P. Huston 📂 Article 📅 1993 🏛 Elsevier Science 🌐 French ⚖ 75 KB

Primate model of Parkinson's disease: al

✍ Nadav Zamir; Gerhard Skofitsch; Michael J. Bannon; Cinda J. Helke; Irwin J. Kopi 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 365 KB